Rømer, Troels Boldt http://orcid.org/0000-0002-0832-2667
Aasted, Mikkel Koed Møller http://orcid.org/0000-0001-7237-7948
Dabelsteen, Sally
Groen, Aaron
Schnabel, Julia
Tan, Edwin
Pedersen, Johannes Wirenfeldt
Haue, Amalie Dahl http://orcid.org/0000-0001-7656-7976
Wandall, Hans Heugh http://orcid.org/0000-0003-0240-9232
Funding for this research was provided by:
University of Copenhagen | Det Sundhedsvidenskabelige Fakultet, Københavns Universitet
Kræftens Bekæmpelse
The NEYE Foundation
Article History
Received: 21 December 2020
Revised: 8 July 2021
Accepted: 17 August 2021
First Online: 15 September 2021
Competing interests
: HHW owns stocks and is a consultant for and co-founder of EbuMab, ApS. and GO-Therapeutics, Inc. JWP, HHW and MKMA are co-inventors of a novel antibody targeting truncated O-glycans. The remaining authors declare no competing interests. AG, JS and ET are employed by GO-Therapeutics, Inc.
: TMA material was obtained from US Biomax, Inc. The company informs that all human tissues are collected under HIPPA approved protocols, with full information of the donor and with their consent. All standard medical care has been followed, and protection of the donors’ privacy has been ensured.
: TMA material from US Biomax, Inc. is collected with full information of the donor and consent to use tumour material for research purposes, including publication of results.